Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib

Clinical and Translational Oncology

Volumn 10, Issue 12, 2008, Pages 831-839

  Paz Ares, Luis ^a   García Del Muro, Xavier ^b   Grande, Enrique ^c   González, Paloma ^c   Brosa, Max ^d   Díaz, Silvia ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c PFIZER INC   (United States)

^d Oblikue Consulting   (Spain)

Author keywords

Cost effectiveness; GIST; Spain; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PLACEBO; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

ADJUVANT CHEMOTHERAPY; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESISTANCE; ECONOMICS; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE PLANNING; HUMAN; METASTASIS; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL; TREATMENT FAILURE; UTILIZATION REVIEW;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HEALTH RESOURCES; HUMANS; INDOLES; MARKOV CHAINS; MODELS, ECONOMETRIC; NEOPLASM METASTASIS; PIPERAZINES; PLACEBOS; PYRIMIDINES; PYRROLES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 60549093884     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-008-0297-3     Document Type: Article

References (43)

1. Muñoz C, Sabah S, Navarro A et al (2006) Tumores del estroma gastrointestinal: una revisión de la literatura. Gastr Latinoam 1:43-51
2. Goettsch WG, Bos SD, Breekveldt-Postma N et al (2005) Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 41:2868-2872
3. Nilsson B, Bumming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era; a population based study in western Sweden. Cancer 103:821-829
4. Mucciarini C, Rossi G, Bertolini F et al (2004) Gastrointestinal stromal tumors (GIST): Evaluation on malignancy and prognosis in 113 cases retrieved from a population based cancer registry of northern Italy. ASCO [Abstract 4232]
5. Ringenbach F, Viennet G, Monnien F et al (2005) Prevalence of GISTs in primary benign and malignant mesenchymal neoplasms of the gastrointestinal tract and the abdomen: preliminary pathological retrospective study of 180 cases from 1990 to 2000. ASCO GI Cancer Symp [Abstract 20]
6. Tryggvasson G, Gislason H, Magnusson M et al (2005) Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117:289-293
7. Miettinen M, Lasota J (2003) Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54:3-24
8. Blanke CD, Eisemberg BL, Heinrich MC et al (2001) Gastrointestinal stromal tumors. Current Trat Options Oncol 6:1-5
9. De Pas T, Casali PG, Toma S et al (2003) Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?. Oncology 64:186-188
10. Garcia-del-Muro X, López-Pousa A, Buesa JM et al (2001) Temozolamide as a 6-week continuous oral Schedule in advanced sofá tissue sarcomas (STS): a phase II trial of the Spanish Group for Research on Sarcomas (GEIS). Proc Ann Meet Am Soc Clin Oncol 20:A354
11. Ryan DP, Puchalsky T, Supko JG et al (2002) A phase II and pharmacokinetics of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 7:531-538
12. Patel SR, Gandhi V, Jenkins J et al (2001) Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19:3483-3489
13. Corless CL, McGreevey L, Haley A et al (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimetre or less in size. Am J Pathol 160:1567
14. Ng EH, Pollock RE, Munsell MF et al (1992) Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 215:268
15. McGrath PC, Neifeld JP, Lawrence W et al (1987) Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 206:706
16. Rossi CR, Mocellin S, Mencarelli R et al (2003) Gastrointestinal stromal tumors: from a surgical to a molecular approach. Int J Cancer 107:171-176
17. Duffaud F, Blay JY (2003) Gastrointestinal stromal tumors: biology and treatment. Oncology 65:187-197
18. de Silva CM, Reid R (2003) Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 9:13-19
19. Miettinen M, Lasota J (2003) Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54:3-24
20. Casper ES (2000) Gastrointestinal stromal tumors. Curr Treat Options Oncol 1:267-273
21. Demetri GD, Von Meheren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480
22. Van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I stu dy. Lancet 358:1421-1423
23. Van Oosterom AT, Judson I, Verweij J et al (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38: S83-S87
24. Benjamin RS, Rankin C, Fletcher C et al (2003) Phase III dose randomized study of imatinib mesylate (STI571) for GIST: intergroup S0033 early results (abstract 3271). Proc Am Soc Clin Oncol 22:814
25. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free-survival in gastrointestinal stromal tumors with high dose imatinib: randomized trial. Lancet 364:1127-1134
26. European Medicines Agency. Sutent European Public Assessment Report. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/sutent/sutent.htm (published 17.12.07; accessed: 11.01.08)
27. Goodman VL, Rock EP, Dagher R et al (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367-1373
28. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338
29. Catálogo de Especialidades Farmacéuticas. Consejo General de Colegios Oficiales de Farmacéuticos. Available at: http://www.portalfarma.com (accessed: 23.03.07)
30. Oblikue Consulting. Base de Datos de Costes Sanitarios eSalud. Available at: http://www.oblikue.com/bddcostes/
31. Ojeda B, de Sande LM, Casado A et al (2003) Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer 89:1002-1007
32. Wilson J, Connock M, Song F et al (2005) Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 25:33-45
33. Huse DM, von Mehren M, Lenhart G et al (2007) Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Investig 27:85-93
34. Chabot I, LeLorier J, Blackstein ME (2008) The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer 44:972-7
35. Demetri GD, Huang X, Garret CR et al. Novel statistical analysis of long term survival to account for cross-over in a phase III trial of sunitinib versus placebo in advanced GIST after imatinib failure. 2008 ASCO Annual Metting. [Abstract 10524]
36. Aguilar M, Fernández S, González P et al (2007) Pharmacoeconomic impact of the sunitinib adverse events (AEs) prophylaxis treatment in Spain. Drug Safety 30:960 [Abstract P.090]
37. Barbieri M, Drummond M, Willke R et al (2005) Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 8:10-23
38. Rocchi A, Menon D, Verma S, Millar E (2007) The role of economic evidence in Canadian reimbursement decision-making: to lambda and beyond. Value Health 4:771-783
39. Nadler E, Eckert B, Neumann PJ (2006) Do oncologist believe new caner drugs offer good value? Oncologist 11:90-95
40. Grusenmeyer AP, Wong YN (2007) Interpreting the economic literature in oncology. J Clin Oncol 25:196-202
41. Drummond MF, Mason AR (2007) European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 25:191-195
42. Raftery J (2006) Review of NICE's recommendations, 1999-2005. Br Med J 332:1266-1268
43. Uyl-de-Groot CA (2006) Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care. Eur J Cancer 42:2862-2866